Host |
Mouse |
Klon |
BGN/1F8 |
Format |
Purified |
Methode |
F, P, EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to amino acids 1-34 of mature PTH conjugated to a proprietary carrier molecule |
Parathyroid Hormone (PTH)
|
Zytomed Systems GmbH |
BGN/1F8 |
200 µg |
Purified |
RUO |
616-0067 |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
1.0 ml |
Concentrate |
CE/IVD |
Z2378ML |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
7 ml |
Ready-to-use |
CE/IVD |
Z2378MP |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
0.5 ml |
Concentrate |
CE/IVD |
Z2378MS |
-
|
Host |
Mouse |
Klon |
ZM207 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Parathyroid. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
A synthetic peptide around aa 1-34 of human mature-PTH-polypeptide; A recombinant fragment around aa 32-115 of human mature PTH-polypeptide (exact sequence is proprietary) |
Lokalisation |
Cytoplasm |
Parathyroid hormone (PTH)
|
Zeta Corporation |
ZM207 |
0.1 ml |
Concentrate |
CE/IVD |
Z2378MT |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
1 ml |
Concentrate |
CE/IVD |
Z2741RL |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
7 ml |
ready-to-use |
CE/IVD |
Z2741RP |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
0.5 ml |
Concentrate |
CE/IVD |
Z2741RS |
-
|
Host |
Rabbit |
Klon |
ZR224 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Renal cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 223-354) of human PAX2 protein |
Lokalisation |
nucleus |
PAX-2
|
Zeta Corporation |
ZR224 |
0.1 ml |
Concentrate |
CE/IVD |
Z2741RT |
-
|
Host |
Rabbit |
Klon |
SP34 |
Format |
Concentrate |
Reaktivität |
CK, DG, MS |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
0.1 ml |
Concentrate |
RUO |
530-3340 |
-
|
Host |
Rabbit |
Klon |
SP34 |
Format |
Concentrate |
Reaktivität |
CK, DG, MS |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
0.5 ml |
Concentrate |
RUO |
530-3342 |
-
|
Host |
Rabbit |
Klon |
SP34 |
Format |
Concentrate |
Reaktivität |
CK, DG, MS |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from C-terminus of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zytomed Systems GmbH |
SP34 |
1 ml |
Concentrate |
RUO |
530-3344 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
1 ml |
Concentrate |
CE/IVD |
Z2354ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2354MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2354MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human full-length PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZM26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2354MT |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
1 ml |
Concentrate |
CE/IVD |
Z2582RL |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
7 ml |
Ready-to-use |
CE/IVD |
Z2582RP |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
0.5 ml |
Concentrate |
CE/IVD |
Z2582RS |
-
|
Host |
Rabbit |
Klon |
ZR268 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa 235-382) of human PAX-5 protein |
Lokalisation |
Nucleus |
PAX-5
|
Zeta Corporation |
ZR268 |
0.1 ml |
Concentrate |
CE/IVD |
Z2582RT |
-
|
Host |
Mouse |
Klon |
BC12 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Kidney, renal cell carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Verdünnung |
ag0306 |
Lokalisation |
Nucleus |
PAX-8
|
Diagnostic Biosystems |
BC12 |
6 ml |
Ready-to-use |
CE/IVD |
PDM180 |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2202RL |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2202RP |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2202RS |
-
|
Host |
Rabbit |
Klon |
ZR1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of Human PAX8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZR1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2202RT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
1 ml |
Concentrate |
CE/IVD |
Z2357ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
7 ml |
Ready-to-use |
CE/IVD |
Z2357MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
0.5 ml |
Concentrate |
CE/IVD |
Z2357MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM28 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Ovarian serous carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human PAX-8 protein |
Lokalisation |
Nucleus |
PAX-8
|
Zeta Corporation |
ZM28 |
0.1 ml |
Concentrate |
CE/IVD |
Z2357MT |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Breast cancer or prostate cancer |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant rat PCNA protein |
Lokalisation |
Nucleus |
PCNA (PC10)
|
Biocare Medical |
PC10 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3255G |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
P, EL, WB |
Positivkontrolle |
Breast |
Verdünnung |
2.5 µg/mL |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding an internal region of human PCNA protein |
PCNA (Proliferating Cell Nuclear Antigen)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
616-0350 |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
1 ml |
Concentrate |
CE/IVD |
MOB083 |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB083-01 |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB083-05 |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM014 |
-
|
Host |
Mouse |
Klon |
PC10 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Nucleus |
PCNA (Proliferating Cell Nuclear Antigen)
|
Diagnostic Biosystems |
PC10 |
25 ml |
Ready-to-use |
CE/IVD |
PDM014-25 |
-
|
Host |
Mouse |
Klon |
EH33 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a+IgG1 kappa |
Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
1 ml |
Concentrate |
CE/IVD |
MOB573 |
-
|
Host |
Mouse |
Klon |
EH33 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a+IgG1 kappa |
Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
0.1 ml |
Concentrate |
CE/IVD |
MOB573-01 |
-
|
Host |
Mouse |
Klon |
EH33 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a+IgG1 kappa |
Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
0.5 ml |
Concentrate |
CE/IVD |
MOB573-05 |
-
|
Host |
Mouse |
Klon |
EH33 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG2a+IgG1 kappa |
Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
6 ml |
Ready-to-use |
CE/IVD |
PDM573 |
-
|
Host |
Mouse |
Klon |
EH33 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG2a+IgG1 kappa |
Verdünnung |
Recombinant protein fragment corresponding to the extracellular domain ofhuman PD-1 (as an Ig fusion protein) |
Lokalisation |
Cell membrane, cytoplasm |
PD-1
|
Diagnostic Biosystems |
EH33 |
25 ml |
Ready-to-use |
CE/IVD |
PDM573-25 |
-
|
Host |
Mouse |
Klon |
NAT105 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3137AK |
-
|
Host |
Mouse |
Klon |
NAT105 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasmic |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
1 ml |
Concentrate |
CE/IVD |
ACI3137CK |
-
|
Host |
Rabbit |
Klon |
CAL20 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG1 |
Lokalisation |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3224A |
-
|
Host |
Rabbit |
Klon |
CAL20 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG1 |
Lokalisation |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3224B |
-
|
Host |
Mouse |
Klon |
NAT105 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
PD-1 (CD279)
|
Biocare Medical |
NAT105 |
6 ml |
Ready-to-use |
CE/IVD |
API3137AA |
-
|
Host |
Rabbit |
Klon |
EP239 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma, colon cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Cytoplasm, cell membrane |
PD-1 (CD279)
|
Biocare Medical |
EP239 |
6 ml |
Ready-to-use |
CE/IVD |
API3162AA |
-
|
Host |
Rabbit |
Klon |
CAL20 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG1 |
Lokalisation |
Cytoplasm and cell membrane |
PD-1 (CD279)
|
Biocare Medical |
CAL20 |
6 ml |
Ready-to-use |
CE/IVD |
API3224AA |
-
|
Host |
Mouse |
Klon |
ZM357 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph Node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /k |
Verdünnung |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
Lokalisation |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
1 ml |
Concentrate |
CE/IVD |
Z2424ML |
-
|
Host |
Mouse |
Klon |
ZM357 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph Node |
Verdünnung |
- |
Isotyp |
IgG1 /k |
Verdünnung |
Recombinant fragment (around aa1-200) of human PDCD1 protein |
Lokalisation |
Cytoplasm, Cell Membrane |
PD-1 (PDCD1)
|
Zeta Corporation |
ZM357 |
7 ml |
Concentrate |
CE/IVD |
Z2424MP |
-
|